sovateltide Report issue

Biologics Peptide Experimental
AACT MeSH PubChem

Active Ingredient History

NOW
  • Now

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: No
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Alternative names

endothelin-1 (8-21), succinyl-(glu(9),ala(11,15))- | irl 1620 | irl-1620 | l-tryptophan, n-(3-carboxy-1-oxopropyl)-l-alpha-aspartyl-l-alpha-glutamyl-l-alpha-glutamyl-l-alanyl-l-valyl-l-tyrosyl-l-phenylalanyl-l-alanyl-l-histidyl-l-leucyl-l-alpha-aspartyl-l-isoleucyl-l-isoleucyl-fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone, hemihydrate | spi-1620 | succinyl-(glu(9),ala(11,15))-endothelin-1 (8-21) | succinyl-(glutamyl(9)-alanyl(11,15))-endothelin-1 (8-21)

Organizations (2)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (13)

Approved Indications (1)


 

Carcinoma

Experimental Indications - Clinical Trial Phases 1-4 (13)


 

Acute Febrile Encephalopathy (Phase 2)

Alzheimer Disease (Phase 2)

Biliary Tract Neoplasms (Phase 2)

Brain Ischemia (Phase 4)

Carcinoma (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Cerebral Infarction (Phase 3)

Dementia (Phase 2)

Hypoxia-Ischemia, Brain (Phase 2)

Ischemic Stroke (Phase 3)

Neonatology (Phase 2)

Spinal Cord Injuries (Phase 2)

Stroke (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue